A Phase 2a Randomized, Double-blind, Placebo-Controlled, Crossover Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2016
At a glance
- Drugs VX 150 (Primary)
- Indications Osteoarthritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 03 Oct 2016 Status changed from active, no longer recruiting to completed.
- 29 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 27 Apr 2016 According to Vertex media release, this trial was initiated in the first quarter of 2016 and expects to complete enrolment in the second half of 2016.